EPCAM and neoplasm: Both murine SCC VII and primary human tumor cells collected from patients with HNSCC responded similarly in vitro to Rho kinase inhibition, which promoted a CD44hi tCSC phenotype additionally associated with coexpression of other stem cell markers including ALDH1A1, EpCAM, and EGFR (Supplemental Figure 1, B–D) (10).